ADA 2022: Top 7 Sessions Coverage
Do check these newsletters that capture the latest scientific and clinical discoveries from the recent ADA 2022 sessions held over 5 days in Orleans in the field of type 2 diabetes and associated comorbidities, and advances in diabetes management.
Top 7 Topics
- Top 5 nutrition controversies
- Prevention or delay of type 2 diabetes and associated comorbidities
- Mitigating ASCVD risk in diabetes: Role of kidney in ASCVD
- From paper to practice: Preventing diabetes foot complications
- What is new in diabetic retinopathy screening and grading?
- Hypoglycemia, CGM metrics and HbA1c: Patient and clinician perspectives
- Heterogeneity of diabetes
Top 7 Topics
- Stigma in diabetes care (with Richard R. Rubin award lecture)
- Precision diabetes medicine: A joint ADA/EASD initiative
- Solving the riddle of perplexing diabetes foot topics in primary care
- NAFLD in diabetes: An overlooked complication?
- Weighing the evidence: Should obesity be the primary target?
- Is time in range the gold standard in glucose management?
- Timing of eating and exercise in metabolic health
Top 7 Topics
- New hope, old challenges in heart failure
- Emerging directions in diabetic neuropathy
- Complication compendium: The overlooked offenders
- Improving diabetes care for older adults
- Recent advances in the management of obesity and T2D in youth
- Health disparities, risk of hypoglycemia and treatment options
- Pancreas transplantation in the 21 century
Top 7 Topics
- Joint ADA/ASN symposium: Turning the tides (diabetic kidney disease)
- Breakthrough! Effective treatments for diabetic kidney disease
- Joint ADA/EASD: Management of hyperglycemia in type 2 diabetes
- Diabetes with cardiomyopathy: Does anybody have a map?
- Updates on inpatient diabetes management
- Individualizing diabetes care and education: Children, teens and young adults
- Definition and interpretation of remission in type 2 diabetes
Top 7 Topics
- Machine learning in diabetes
- Novel mechanisms of diabetic kidney disease
- With the eyes to future: A 2022 view of DPN opportunities
- Future of diabetes: The next frontier with dual incretin
- The future of insulin: Weekly, oral, smart or interchangeable therapies
- Positive impact of DCESs on theerapeutic inertia
- Obesity management as a primary goal: It's time for a paradigm shift